泰林生物
(300813)
| 流通市值：15.56亿 | | | 总市值：22.16亿 |
| 流通股本：8512.61万 | | | 总股本：1.21亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 254,923,363.93 | 165,382,315.28 | 70,063,538.95 | 339,538,843.84 |
| 营业总成本 | 237,825,130.92 | 148,978,158 | 66,596,113.34 | 329,644,577.8 |
| 其他经营收益 | | | | |
| 营业利润 | 30,860,141.57 | 21,872,211.34 | 5,374,760.91 | 16,938,093.32 |
| 利润总额 | 30,188,912.67 | 21,609,388.01 | 5,282,600.1 | 16,738,716.51 |
| 净利润 | 28,077,251.52 | 20,372,823.69 | 4,840,310.83 | 16,286,074.7 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 28,077,251.52 | 20,372,823.69 | 4,840,310.83 | 16,286,074.7 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 545,965,608.24 | 523,518,661.87 | 552,049,147.55 | 549,849,767.91 |
| 非流动资产: | | | | |
| 非流动资产合计 | 416,278,921.22 | 414,245,987.13 | 394,858,195.29 | 409,122,815.48 |
| 资产总计 | 962,244,529.46 | 937,764,649 | 946,907,342.84 | 958,972,583.39 |
| 流动负债: | | | | |
| 流动负债合计 | 153,783,833.64 | 144,855,136.28 | 137,913,485.1 | 152,135,819.45 |
| 非流动负债: | | | | |
| 非流动负债合计 | 2,248,346.51 | 2,184,366.92 | 2,545,336.65 | 2,545,336.65 |
| 负债合计 | 156,032,180.15 | 147,039,503.2 | 140,458,821.75 | 154,681,156.1 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 806,212,349.31 | 790,725,145.8 | 806,448,521.09 | 804,291,427.29 |
| 股东权益合计 | 806,212,349.31 | 790,725,145.8 | 806,448,521.09 | 804,291,427.29 |
| 负债和股东权益合计 | 962,244,529.46 | 937,764,649 | 946,907,342.84 | 958,972,583.39 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 331,265,714.85 | 201,678,247.37 | 88,775,297.84 | 355,762,860.49 |
| 经营活动现金流出小计 | 285,253,782.82 | 180,577,677.89 | 92,332,308.73 | 308,040,851.05 |
| 经营活动产生的现金流量净额 | 46,011,932.03 | 21,100,569.48 | -3,557,010.89 | 47,722,009.44 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,252,807,517.9 | 817,940,739.86 | 361,909,860.58 | 1,250,388,212.49 |
| 投资活动现金流出小计 | 1,182,134,003.53 | 726,382,304.26 | 291,774,544.5 | 1,247,985,597.33 |
| 投资活动产生的现金流量净额 | 70,673,514.37 | 91,558,435.6 | 70,135,316.08 | 2,402,615.16 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 17,051,580 | - | - | 11,174,000 |
| 筹资活动现金流出小计 | 47,937,669.06 | 35,885,014.98 | 47,169.81 | 51,898,869.94 |
| 筹资活动产生的现金流量净额 | -30,886,089.06 | -35,885,014.98 | -47,169.81 | -40,724,869.94 |
| 汇率变动对现金及现金等价物的影响 | -1,149,766.14 | -455,933.89 | -422,963.92 | -732,533.59 |
| 现金及现金等价物净增加额 | 84,649,591.2 | 76,318,056.21 | 66,108,171.46 | 8,667,221.07 |
| 期末现金及现金等价物余额 | 163,194,894.73 | 154,863,359.74 | 144,653,474.99 | 78,545,303.53 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 76,318,056.21 | - | 8,667,221.07 |